文献速递甲状腺疾病

放射性碘治疗等待时间对N1期甲状腺乳头状癌结局的影响

Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该回顾性队列研究纳入909例N1期甲状腺乳头状癌患者,分析全甲状腺切除至首次放射性碘治疗等待时间对结局的影响。递归分割分析确定最佳阈值为88天,超过88天者疾病持续/复发风险增加(OR 2.47,95%CI 1.60-3.82)。延迟治疗的预测因素包括低收入地区居住、再次手术、非大学附属医院手术、多灶性、甲状腺外侵犯、N1b期及刺激后甲状腺球蛋白<1 ng/mL。

要点

  • N1期甲状腺乳头状癌患者全甲状腺切除后放射性碘治疗等待时间超过88天与疾病持续/复发风险增加相关。
  • 延迟放射性碘治疗的预测因素包括低收入地区居住、再次手术、非大学附属医院手术、多灶性、甲状腺外侵犯、N1b期及刺激后甲状腺球蛋白<1 ng/mL。
  • 识别延迟治疗预测因素可能有助于靶向高危患者并促进干预。

核心结论

  • N1期甲状腺乳头状癌患者全甲状腺切除后延迟放射性碘治疗超过88天独立增加疾病持续/复发风险。

研究设计与样本

  • 回顾性队列研究,于大学医院开展,纳入2014年至2018年间转诊接受放射性碘治疗的909例N1期甲状腺乳头状癌患者。

主要发现

  • 区分长期缓解/极佳反应结局较差的最佳等待时间阈值为大于88天(占队列51%,n=464)。
  • 调整后,等待时间超过88天与疾病持续/复发风险增加相关(OR 2.47,95%CI 1.60-3.82)。
  • 延迟放射性碘治疗的预测因素包括低收入地区居住、初次放射性碘治疗前再次手术、非大学附属医院全甲状腺切除、多灶性、甲状腺外侵犯、N1b期及放射性碘治疗前刺激后甲状腺球蛋白水平小于1 ng/mL。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The waiting time for radioactive iodine therapy (WRAIT) after total thyroidectomy (TT) in patients with papillary thyroid cancer (PTC) and lymph node metastases (N1) has not been sufficiently investigated for risk of adverse outcomes. OBJECTIVE: This work aimed to estimate the effect of WRAIT on the outcomes of disease persistence and recurrence among patients with N1 PTC and investigate factors predictive of delayed radioactive iodine therapy (RAIT). METHODS: This retrospective cohort study was conducted in a university hospital. A total of 909 patients with N1 PTC were referred for RAIT between 2014 and 2018. WRAIT is the duration between TT and initial RAIT. The optimal WRAIT threshold determined using recursive partitioning analysis was used to define early and delayed RAIT. The primary end point was tumor persistence/recurrence. We compared the outcomes of patients with early and delayed RAIT using inverse probability weighting based on the propensity score. RESULTS: The WRAIT threshold that optimally differentiated worse long-term remission/excellent response outcomes was greater than 88 days (51% of our cohort; n = 464). WRAIT exceeding 88 days was associated with an augmented risk of disease persistence/recurrence (odds ratio, 2.47; 95% CI, 1.60-3.82) after adjustment. Predictors of delayed RAIT included residence in lower-income areas, reoperation before the initial RAIT, TT at a nonuniversity-affiliated hospital, multifocality, extrathyroidal extension, N1b disease, and pre-RAIT-stimulated thyroglobulin level less than 1 ng/mL. CONCLUSION: Delayed RAIT beyond 88 days after TT in patients with N1 PTC independently increased the risk of disease persistence/recurrence. Evaluation of the predictive determinants of prolonged WRAIT may help target at-risk patients and facilitate interventions.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sun Y, Sun Q, Tian J, et al. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer. J Clin Endocrinol Metab. 2023. PMID: 37167097. doi:10.1210/clinem/dgad264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。